Using fecal calprotectin as a companion biomarker to microbiome analysis in dogs

Microbiome analysis can show how a dog’s bacterial community differs from a healthy or diseased pattern, but it does not reveal whether those differences cause inflammation. Pairing canine microbiome sequencing with faecal calprotectin measurements adds a measure of the host response: activated leukocytes release calprotectin, which remains relatively stable in faeces and rises with intestinal mucosal inflammation.

Calprotectin is not a direct label for dysbiosis. It cannot identify a pathogen, replace culture or, by itself, distinguish dietary dysfunction from inflammatory bowel disease, parasitic infection or neoplasia. Its value is to add an objective dimension to serial investigations when chronic diarrhoea is uncertain and bloodwork is equivocal.

Australian clinics encounter these questions in varied settings. Owners in Sydney and Melbourne often exercise dogs in dense suburbs, apartment complexes and shared off-leash parks, while Brisbane and Adelaide require careful sample transport in hot weather. Routines may include commercial food, treats, table scraps and supplements. The local market also supports veterinary diets, probiotics and direct-to-consumer microbiome testing.

Hill’s ActivBiome provides on-demand recordings, expert presentations and downloadable resources on the canine and feline microbiome. Collaborations with Harvard T.H. Chan School of Public Health, Texas A&M University and the University of Vienna translate current science into professional education.

What calprotectin measures

Calprotectin is a calcium-binding protein found mainly in neutrophils and monocytes. As these cells accumulate in inflamed intestinal tissue, faecal concentration can increase. It is therefore a marker of intestinal inflammation, not microbial balance. It may support suspicion of active mucosal disease and gauge change over time, but must be compared with the laboratory’s validated canine interval and assay method.

Concentrations vary with faecal consistency, age, diet and medication, and healthy and affected ranges overlap. A raised result can accompany acute enteritis, infection or chronic immune-mediated disease; a low result does not exclude every important disorder. Sampling before antibiotics is useful when safe, but treatment should not be delayed for a specimen.

Reading the marker beside microbial data

Microbiome sequencing, whether 16S rRNA or shotgun metagenomics, describes community composition and sometimes functional potential. It is sensitive to collection method, DNA extraction, sequencing batch and database choice. Calprotectin measures a different axis. Changes in diversity alongside rising calprotectin may support active inflammation, while an unremarkable marker may prompt reconsideration of infection, obstruction, dysmotility or extra-gastrointestinal disease.

Neither result should be judged against a generic healthy microbiome. Dog communities vary with age, breed, size, diet, location and medication. Repeated samples collected by the same method under similar dietary conditions are more informative. Use calprotectin trends to frame changes in diversity or microbial functions, then investigate with culture, parasite testing, imaging, blood markers or histopathology as indicated.

Collecting reliable samples in Australian conditions

Fresh stool is required, and the container depends on the test. A laboratory may request a sterile container, while microbiome workflows often use transport buffer or DNA-stabilising medium. Do not transfer a microbiome sample into a calprotectin tube unless instructions allow it. Record consistency, colour, blood or mucus, collection date and medication; hard pellets and loose faeces are not directly comparable.

In hot Australian conditions, prompt refrigeration or the laboratory’s validated freezing protocol matters. Samples should not remain in a warm car, reception bowl or letterbox. Refrigerate at the stated temperature and use supplied courier packaging. For suspected infectious material, follow the laboratory’s transport and biosecurity instructions, including dangerous-goods documentation where applicable.

Building an Australian clinic workflow

Begin with a defined clinical question rather than ordering both tests by default. Document diet and medication history, examine the patient, collect faeces for routine parasitology and calprotectin, and decide whether sequencing is likely to change management. For stable chronic enteropathy, serial calprotectin and selected blood tests may be more informative than repeated broad microbial panels.

Urban Australian routines can confound patient and sample. Off-leash park access raises exposure to parasites and other dogs, while apartment households may describe noise, separation stress and irregular toileting. Ask about travel, boarding, raw diets, new foods and treat intake. In Brisbane or Adelaide summer heat, arrange home and courier collection under validated conditions. Clinic teams interested in staff education can contact ActivBiome to discuss the webinar resources.

Regulation and the local testing market

Any in-vitro diagnostic assay marketed for clinical use needs a clear intended purpose and lawful Australian supply status. The Therapeutic Goods Administration regulates medical devices; sponsors may need Australian conformity assessment and Australian Register of Therapeutic Goods inclusion, although exemptions can apply in specified circumstances. Teams should check Australian instructions rather than assuming overseas certification or a consumer microbiome report meets local requirements.

Veterinary medicines, including registered parasiticides and some digestive preparations, sit under the Australian Pesticides and Veterinary Medicines Authority, whereas many supplements and probiotics occupy different regulatory categories. Claims should distinguish health screening, research use and clinical diagnosis. Local council waste rules remain relevant when clients collect faeces from public parks, as disposal requirements differ between municipal areas.

The Australian market also offers online microbiome panels alongside veterinary gut diets, prebiotics and probiotics, making transparent communication about each test’s limitations essential.

Interpreting common clinical patterns

Interpret patterns rather than isolated thresholds. A marked calprotectin increase with reduced diversity and broader community change may strengthen a case for active enteropathy, but it does not prove a diagnosis. A normal or mildly increased result does not exclude mild chronic disease, functional pain or neoplasia. Albumin, globulin, haematology, C-reactive protein, imaging and biopsy remain complementary.

Serial measurement can help evaluate change after dietary correction, antimicrobial treatment or immunomodulation. Establish a baseline and resample under similar conditions with the same assay, considering absolute and percentage change because biological and assay variation affect both. A falling concentration with better clinical scores supports control of inflammation; persistence warrants reassessment rather than indiscriminate changes to therapy.

Extending education across the veterinary team

Hill’s ActivBiome webinar resources help teams connect host inflammation with microbiome findings. Expert presentations and downloadable material give clinicians, nurses and practice managers a shared vocabulary for discussing why an apparently abnormal microbiome may have limited clinical meaning, and why calprotectin remains one piece of evidence. Case-based discussion can clarify when sequencing is likely to influence management.

Participants who meet the stated requirements can obtain a certificate after the activity. The programme supports conversations about test limitations, diet consistency, responsible antimicrobial use and explaining uncertainty without reducing care to a single microbiome score.